In March 2025, Sen-Jam Pharmaceutical hosted a pivotal webinar in collaboration with Destum Partners, a premier strategic advisory firm known for driving success in biotech partnerships, licensing, and M&A. This exclusive session offered investors and industry insiders a rare look behind the curtain—where scientific innovation meets commercial strategy. With several of our leading assets entering Phase 2 clinical milestones and patent protections expanding globally, the timing of this conversation could not have been more crucial. Together with Destum, we outlined our roadmap for unlocking value through co-development and licensing agreements, showcasing how our pipeline aligns with current market opportunities in public health, respiratory infection, addiction recovery, and next-gen anti-inflammatories.